Inventiva Past Earnings Performance
Past criteria checks 0/6
Inventiva's earnings have been declining at an average annual rate of -47.6%, while the Biotechs industry saw earnings growing at 18.5% annually. Revenues have been growing at an average rate of 13.6% per year.
Key information
-47.62%
Earnings growth rate
-21.67%
EPS growth rate
| Biotechs Industry Growth | 30.80% |
| Revenue growth rate | 13.62% |
| Return on equity | n/a |
| Net Margin | -5,237.95% |
| Next Earnings Update | 25 Sep 2026 |
Recent past performance updates
Recent updates
Narrative Update • Jun 17
IVA: Equity Raise And New Financing Will Support Upcoming MASH Milestones
Analysts have adjusted their price target on Inventiva to €15.37 from €11.40, citing updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E, along with recent Street research such as Stifel's revised target. What's in the News for Inventiva Inventiva completed a follow on equity offering of American Depositary Shares, raising about US$120.0 million through the issuance of 27,272,727 ADSs at a price of US$4.40 per security, at a discount of US$0.264 per ADS.
Narrative Update • Jun 03
IVA: 2026 MASH Phase 3 Milestones Will Drive Bullish Repricing Potential
Analysts have nudged their fair value estimate for Inventiva slightly higher to about €10.09, reflecting updated assumptions on the discount rate and future P/E following a lower price target from Stifel and a fresh bullish initiation from Truist. Analyst Commentary Recent research views on Inventiva point in different directions, with bullish analysts focusing on long term upside potential and bearish analysts placing more weight on execution risks and valuation discipline.Narrative Update • May 19
IVA: 2026 MASH Phase 3 Readout Will Underpin Bullish Repricing Outlook
Analysts have trimmed their fair value estimate for Inventiva slightly from about €10.00 to about €9.97, pointing to updated assumptions around profit margins and a higher future P/E that balance recent caution from one research house with a more bullish initiation from another. Analyst Commentary Bullish Takeaways Bullish analysts see the slightly higher assumed future P/E as support for the idea that investors may be willing to pay up for the stock if execution on the current pipeline stays on track.Narrative Update • May 04
IVA: 2026 MASH Phase 3 Readout Will Drive Repricing Thesis
Analysts have trimmed their price target on Inventiva by €2, reflecting slightly more cautious revenue growth assumptions, expectations for stronger profit margins, and a marginally lower future P/E multiple. Analyst Commentary Bullish Takeaways Bullish analysts see the revised price target as still consistent with meaningful upside potential if Inventiva can deliver on revenue expectations and margin improvement.Narrative Update • Apr 20
IVA: 2026 MASH Phase 3 Readout Will Support Repricing Thesis
Analysts now see Inventiva’s fair value holding at €10.00, with the latest price target update explained by a slightly higher discount rate, adjusted revenue growth and margin assumptions, and a lower future P/E multiple following recent initiation and target revision reports from several firms. Analyst Commentary Recent Street research on Inventiva points to a mix of optimism around the long term setup and caution around execution risk.Narrative Update • Apr 06
IVA: 2026 MASH Phase 3 Readout Will Drive Repricing Narrative
The analyst price target for Inventiva has shifted from €8.98 to about €10.00, reflecting updated analyst views that balance a slightly higher discount rate with Street research highlighting lanifibranor's profile in MASH and recent supportive coverage from multiple firms. Analyst Commentary Street research around Inventiva centers on how effectively the company can turn lanifibranor's MASH profile into a de-risked late stage asset and how that potential squares with recent price target resets and rating changes.Narrative Update • Mar 23
IVA: Bullish MASH Program Coverage Will Highlight Upcoming Clinical Milestone Catalysts
The analyst price target for Inventiva has been revised to €11.40. This reflects analysts' use of a slightly higher discount rate, an updated view on very large revenue growth potential, and adjusted future P/E assumptions informed by recent bullish initiations and upgrades on the stock.Narrative Update • Mar 08
IVA: 2026 MASH Phase 3 Readout Expected To Drive Bullish Repricing
Analysts have increased their average price target for Inventiva to €12, up from €3, citing fresh bullish initiations and upgrades that highlight lanifibranor's differentiated profile in metabolic dysfunction-associated steatohepatitis, its inclusion among preferred small and mid cap biotech names with key upcoming catalysts, and its broader pipeline. Analyst Commentary Recent research coverage clusters around a constructive view on Inventiva, with several firms setting price targets around €12 and highlighting both the lead MASH asset and the broader pipeline as key pieces of the story.Narrative Update • Feb 21
IVA: 2026 MASH Phase 3 Readout Will Support Bullish Repricing View
Analysts have raised their Inventiva fair value estimate from €7.85 to approximately €8.98, citing recent Buy and Outperform initiations that underscore confidence in lanifibranor's MASH potential and a modest increase in the assumed future P/E multiple. Analyst Commentary Recent research coverage paints a generally constructive picture for Inventiva, with several firms starting or updating views that focus on lanifibranor's potential in MASH and re-rating the shares using higher P/E assumptions and price targets.Narrative Update • Feb 07
IVA: Bullish Coverage And Equity Raises Will Highlight Upcoming MASH Catalyst
The analyst price target for Inventiva has moved from $10.00 to $11.40 as analysts factor in recent bullish initiations and upgrades that highlight lanifibranor's profile in MASH and identify the company as part of a group with key upcoming catalysts and broader pipelines. Analyst Commentary Bullish analysts are clustering around a constructive view on Inventiva, pointing to recent initiations and upgrades that anchor higher valuation frameworks to the MASH opportunity and the broader pipeline.Narrative Update • Jan 22
IVA: 2026 Phase 3 MASH Readout Will Drive Bullish Repricing Narrative
Narrative Update on Inventiva Analysts have raised their price targets on Inventiva to a range of about US$12 to US$13 per share, up from around US$3 in earlier research. They cite new Outperform and Buy ratings that highlight lanifibranor's pan PPAR profile in MASH and upcoming clinical catalysts as key supports for a higher valuation framework.Narrative Update • Jan 08
IVA: 2026 Phase 3 MASH Readout Expected To Unlock Upside Repricing
Analysts have raised their price target on Inventiva to $12 from $3, citing growing confidence in upcoming lanifibranor data, a broader biotech re-rating, and what they view as a de-risked, best-in-class pipeline with multiple catalysts ahead. Analyst Commentary Recent Street research around Inventiva clusters around a more constructive view of its lead asset lanifibranor and the company’s late stage pipeline, which analysts link directly to their higher valuation frameworks and upgraded views on the stock.Narrative Update • Dec 23
IVA: 2026 Phase 3 MASH Data Will Drive Upside Repricing
Analysts have modestly reduced their price target on Inventiva to $7.85 from $8.20 while maintaining a constructive stance based on expectations that lanifibranor could show superior fibrosis improvement in the pivotal Phase 3 NATiV3 trial, which is expected in the second half of 2026. Analyst Commentary Bullish analysts highlight that despite the modest reduction in the price target, the longer term valuation framework remains driven by the potential of lanifibranor to outperform currently approved MASH therapies on fibrosis endpoints.Narrative Update • Dec 09
IVA: 2026 Phase 3 Fibrosis Data Will Drive Significant Upside Potential
Analysts have modestly raised their price target on Inventiva to $13.00, reflecting increased confidence in lanifibranor's potential for superior fibrosis improvement ahead of the pivotal Phase 3 NATiV3 data, which is expected in the second half of 2026. Analyst Commentary Recent Street research highlights a generally constructive stance on Inventiva, anchored by optimism around lanifibranor's potential differentiation in the emerging MASH treatment landscape and the value inflection expected around the Phase 3 NATiV3 readout in the second half of 2026.Analysis Article • Dec 03
These Analysts Think Inventiva S.A.'s (EPA:IVA) Sales Are Under Threat
The latest analyst coverage could presage a bad day for Inventiva S.A. ( EPA:IVA ), with the analysts making...Narrative Update • Nov 25
IVA: Upcoming 2026 Phase 3 Data Will Unlock Significant Upside Potential
Inventiva's analyst price target has been raised from $7.95 to $8.20 per share. This increase reflects growing optimism among analysts due to increased confidence in lanifibranor's potential Phase 3 efficacy and expanding market opportunities.Narrative Update • Nov 06
IVA: Phase 3 Readout Will Drive Future Upside Amid Bullish Coverage
Analysts have maintained their fair value estimate for Inventiva at $7.95, citing continued optimism around forthcoming Phase 3 data. There is also a growing consensus on the promising outlook for lanifibranor in the MASH market.Analysis Article • Oct 31
The Price Is Right For Inventiva S.A. (EPA:IVA) Even After Diving 30%
Inventiva S.A. ( EPA:IVA ) shares have retraced a considerable 30% in the last month, reversing a fair amount of their...Narrative Update • Oct 23
Analysts Boost Inventiva Price Target Amid Optimism for MASH Market and Pipeline Progress
Analysts have raised their average price target for Inventiva from $9 to $13 per share, citing increased optimism for the Metabolic-Associated Steatohepatitis market as well as a larger anticipated target patient population. Analyst Commentary Bullish Takeaways Bullish analysts have increased their price targets, reflecting heightened enthusiasm for the Metabolic-Associated Steatohepatitis market and an anticipated expansion in the eligible patient population.Narrative Update • Oct 09
Phase III Trials Will Advance Lanifibranor For MASH Treatment
Analysts have increased their fair value estimate for Inventiva from $6.45 to $7.95 per share. They cited greater conviction in revenue growth potential and profit margins for its lead asset in the metabolic disease market.Analysis Article • Oct 08
Revenue Downgrade: Here's What Analysts Forecast For Inventiva S.A. (EPA:IVA)
The latest analyst coverage could presage a bad day for Inventiva S.A. ( EPA:IVA ), with the analysts making...Analysis Article • Sep 04
Need To Know: The Consensus Just Cut Its Inventiva S.A. (EPA:IVA) Estimates For 2025
Today is shaping up negative for Inventiva S.A. ( EPA:IVA ) shareholders, with the analysts delivering a substantial...Analysis Article • Aug 15
There's Reason For Concern Over Inventiva S.A.'s (EPA:IVA) Massive 27% Price Jump
The Inventiva S.A. ( EPA:IVA ) share price has done very well over the last month, posting an excellent gain of 27...
New Narrative • Apr 02
Phase III Trials Will Advance Lanifibranor For MASH Treatment
Strategic focus on lanifibranor development, cutting other activities, and reducing workforce may improve net margins through operational efficiency.Analysis Article • Apr 02
Need To Know: Analysts Are Much More Bullish On Inventiva S.A. (EPA:IVA)
Inventiva S.A. ( EPA:IVA ) shareholders will have a reason to smile today, with the analysts making substantial...Analysis Article • Feb 27
Revenues Not Telling The Story For Inventiva S.A. (EPA:IVA) After Shares Rise 36%
Inventiva S.A. ( EPA:IVA ) shares have had a really impressive month, gaining 36% after a shaky period beforehand. But...Analysis Article • Sep 27
Inventiva S.A. (EPA:IVA) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely
Unfortunately for some shareholders, the Inventiva S.A. ( EPA:IVA ) share price has dived 28% in the last thirty days...Analysis Article • Jun 18
More Unpleasant Surprises Could Be In Store For Inventiva S.A.'s (EPA:IVA) Shares After Tumbling 28%
Inventiva S.A. ( EPA:IVA ) shareholders that were waiting for something to happen have been dealt a blow with a 28...Analysis Article • Jun 14
Shareholders May Not Be So Generous With Inventiva S.A.'s (EPA:IVA) CEO Compensation And Here's Why
Key Insights Inventiva to hold its Annual General Meeting on 20th of June Total pay for CEO Frederic Cren includes...Analysis Article • Mar 19
Optimistic Investors Push Inventiva S.A. (EPA:IVA) Shares Up 27% But Growth Is Lacking
Those holding Inventiva S.A. ( EPA:IVA ) shares would be relieved that the share price has rebounded 27% in the last...Analysis Article • Jan 16
Some Confidence Is Lacking In Inventiva S.A.'s (EPA:IVA) P/S
When close to half the companies in the Biotechs industry in France have price-to-sales ratios (or "P/S") below 5.8x...Revenue & Expenses Breakdown
Revenue & Expenses Breakdown
How Inventiva makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 25 | 7 | -354 | 45 | 83 |
| 30 Sep 25 | 12 | -333 | 35 | 84 |
| 30 Jun 25 | 17 | -311 | 24 | 85 |
| 31 Mar 25 | 16 | -248 | 20 | 86 |
| 31 Dec 24 | 14 | -184 | 17 | 88 |
| 30 Sep 24 | 17 | -144 | 16 | 93 |
| 30 Jun 24 | 19 | -104 | 16 | 99 |
| 31 Mar 24 | 21 | -107 | 15 | 103 |
| 31 Dec 23 | 23 | -110 | 15 | 107 |
| 30 Sep 23 | 22 | -95 | 15 | 94 |
| 30 Jun 23 | 22 | -80 | 15 | 81 |
| 31 Mar 23 | 20 | -67 | 15 | 69 |
| 31 Dec 22 | 18 | -54 | 15 | 57 |
| 30 Sep 22 | 14 | -55 | 13 | 57 |
| 30 Jun 22 | 10 | -56 | 12 | 56 |
| 31 Mar 22 | 10 | -56 | 11 | 53 |
| 31 Dec 21 | 9 | -50 | 11 | 45 |
| 30 Sep 21 | 7 | -45 | 10 | 36 |
| 30 Jun 21 | 6 | -41 | 10 | 26 |
| 31 Mar 21 | 5 | -36 | 9 | 22 |
| 31 Dec 20 | 5 | -34 | 8 | 21 |
| 30 Sep 20 | 7 | -29 | 7 | 23 |
| 30 Jun 20 | 10 | -25 | 6 | 26 |
| 31 Mar 20 | 10 | -27 | 6 | 28 |
| 31 Dec 19 | 11 | -30 | 6 | 32 |
| 30 Sep 19 | 9 | -34 | 6 | 32 |
| 30 Jun 19 | 7 | -37 | 6 | 31 |
| 31 Mar 19 | 8 | -35 | 6 | 30 |
| 31 Dec 18 | 7 | -33 | 6 | 29 |
| 30 Sep 18 | 8 | -29 | 6 | 29 |
| 30 Jun 18 | 9 | -25 | 6 | 28 |
| 31 Mar 18 | 9 | -22 | 6 | 27 |
| 31 Dec 17 | 10 | -19 | 5 | 26 |
| 30 Sep 17 | 11 | -16 | 5 | 25 |
| 30 Jun 17 | 13 | -13 | 5 | 24 |
| 31 Mar 17 | 14 | -10 | 5 | 22 |
| 31 Dec 16 | 14 | -7 | 4 | 21 |
| 30 Sep 16 | 13 | -8 | 4 | 20 |
| 30 Jun 16 | 12 | -8 | 4 | 20 |
| 31 Mar 16 | 10 | -9 | 4 | 19 |
| 31 Dec 15 | 9 | -9 | 4 | 18 |
Quality Earnings: IVA is currently unprofitable.
Growing Profit Margin: IVA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IVA is unprofitable, and losses have increased over the past 5 years at a rate of 47.6% per year.
Accelerating Growth: Unable to compare IVA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IVA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2%).
Return on Equity
High ROE: IVA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/17 21:40 |
| End of Day Share Price | 2026/08/17 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Inventiva S.A. is covered by 24 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Eliana Merle | Barclays |
| Edward Nash | Canaccord Genuity |
| Prakhar Agrawal | Cantor Fitzgerald & Co. |